INSYS THERAP (INSY) Downgraded by Zacks to NEUTRAL

Zacks Investment Research downgraded shares of INSYS THERAP (INSY) from N/A to NEUTRAL on August 06, 2013, with a target price of $18.60.

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on INSYS THERAP (INSY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .